Biohit Oyj, Other information disclosed according to the rules of the Exchange, June 5, 2026 at 6:00 pm local time (EEST)
Biohit Oyj’s Board of Directors has in its meeting on June 5, 2026 elected Professor Kari Syrjänen as the Chairman of the Board of Directors.
Syrjänen’s strong scientific expertise supports the work of the Board of Directors and the development of the company.
Additional information:
CEO Jussi Hahtela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
Biohit in brief
Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com